Please sign in to follow a disease.
Myeloproliferative neoplasm, unclassifiable
MONDO:0019452This subgroup of myeloproliferative neoplasms includes cases which do not meet the morphologic criteria of any of the defined myeloproliferative neoplasms, or which have characteristics that overlap at least two of the myeloproliferative neoplasms.
Also known as: CMPD, U, CMPD-U, MPN, U, MPN-U, chronic myeloproliferative disease, unclassifiable, chronic myeloproliferative disorder, unclassifiable, myeloproliferative neoplasm, unclassifiable, unclassifiable chronic myeloproliferative disease
3069 clinical trials for this condition and its sub-types, 11 tagged with Myeloproliferative neoplasm, unclassifiable itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Myeloproliferative neoplasm, unclassifiable
-
New combo aims to boost transplant success in rare blood cancer
Disease control Recruiting nowThis study tests whether giving a chemotherapy drug (decitabine) plus a targeted therapy (ruxolitinib, fedratinib, or pacritinib) before a stem cell transplant helps people with advanced myeloproliferative neoplasms (MPN) get to transplant and have better outcomes. About 25 adult…
Phase 2 • Sponsor: University of Washington • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New combo therapy for rare blood cancers put on hold
Disease control Recruiting nowThis phase 2 trial compares a drug combo (ASTX727 plus iadademstat) against ASTX727 alone for people with advanced myeloproliferative neoplasms (MPNs), a group of rare blood cancers. The study aims to see if adding iadademstat improves complete response rates. However, the trial …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug combo aims to shrink Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a new antibody called axatilimab, given with or without the chemotherapy drug azacitidine, for people with advanced myeloproliferative neoplasms (MPN), MPN/MDS overlap, or high-risk chronic myelomonocytic leukemia (CMML). The goal is to find the safest dose and s…
Phase 1/2 • Sponsor: Uma Borate • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New drug combo aims to tame rare blood cancers
Disease control Recruiting nowThis early-phase trial tests whether adding the drug momelotinib to standard azacitidine treatment can better control rare blood cancers like chronic myelomonocytic leukemia and chronic neutrophilic leukemia. About 18 adults will take momelotinib pills daily plus azacitidine inje…
Early phase 1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Moving with purpose: new study tests diet and exercise for MPN patients
Symptom relief Recruiting nowThis pilot study tests whether a 12-week nutrition and exercise program is feasible for patients with myeloproliferative neoplasms (MPNs), a group of blood cancers. Thirty participants will take virtual and in-person classes to learn healthier eating and physical activity habits.…
Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Scientists hunt for immune cells that could lead to new MPN therapies
Knowledge-focused Recruiting nowThis study looks at how the immune system reacts to myeloproliferative neoplasms (MPN), a group of blood cancers. Researchers will collect blood and bone marrow samples from 150 adults with or without MPN to find special immune cells (T cells) that recognize and attack MPN cells.…
Sponsor: Université Catholique de Louvain • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Massive new study aims to unlock secrets of rare blood cancers
Knowledge-focused Recruiting nowThis long-term observational study is enrolling 5,000 adults with myeloproliferative neoplasms (MPNs)—rare blood cancers like polycythemia vera and myelofibrosis. Researchers will collect health records, patient surveys, and insurance data over at least five years to track sympto…
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Could your genes predict a rare blood cancer? new study investigates
Knowledge-focused Recruiting nowThis study aims to uncover inherited (germline) genetic factors that make some people more likely to develop myeloproliferative neoplasms (MPNs), a group of blood cancers. Researchers will analyze DNA from 313 patients diagnosed at a young age or with a family history of blood ca…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC